ADReCS

Pharmaceutical Information

Drug Name	Cisplatin
Drug ID	BADD_D00474
Description	Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
Indications and Usage	For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
Marketing Status	approved
ATC Code	L01XA01
DrugBank ID	DB00515
KEGG ID	D00275
MeSH ID	D002945
PubChem ID	5702198
TTD Drug ID	D0U5HU
NDC Product Code	16729-288; 25021-253; 0143-9505; 68554-0077; 0143-9504; 68001-283; 44567-509; 50711-0001; 44567-510; 63323-103; 0703-5747; 0703-5748; 44567-530; 60505-6277; 68083-163; 44567-511; 49452-2078; 54875-0001; 67184-0010; 68083-162; 70860-206; 49812-0009; 72659-864
UNII	Q20Q21Q62J
Synonyms	Cisplatin \| cis-Diamminedichloroplatinum(II) \| Platinum Diamminodichloride \| Diamminodichloride, Platinum \| cis-Platinum \| cis Platinum \| Dichlorodiammineplatinum \| cis-Diamminedichloroplatinum \| cis Diamminedichloroplatinum \| cis-Dichlorodiammineplatinum(II) \| NSC-119875 \| Platino \| Platinol \| Biocisplatinum \| Platidiam

Chemical Information

Molecular Formula	PtCl2(NH3)2
CAS Registry Number	15663-27-1
SMILES	N.N.Cl[Pt]Cl
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Faeces discoloured	07.01.03.002	0.000224%		Not Available
Failure to thrive	18.04.01.003; 14.03.02.008; 19.07.05.001	0.001231%		Not Available
Febrile neutropenia	08.05.02.004; 01.02.03.002	0.008081%
Fibrosis	08.03.01.001	0.000168%		Not Available
Fistula	15.03.02.001	0.000224%		Not Available
Flank pain	20.02.03.006; 15.03.04.003; 08.01.08.007	0.000750%
Flushing	24.03.01.002; 23.06.05.003; 08.01.03.025	0.000806%
Food poisoning	12.03.01.024; 11.07.02.001; 07.11.01.007	-	-	Not Available
Gastric haemorrhage	24.07.02.007; 07.12.01.001	0.000280%
Gastric perforation	07.04.03.001; 12.02.03.007	0.001119%
Gastric ulcer	07.04.03.002	0.000336%
Gastrooesophageal reflux disease	07.02.02.003	-	-
Gastrointestinal necrosis	24.04.08.006; 07.15.01.003	0.000112%
Gastrointestinal perforation	07.04.04.001	0.000112%		Not Available
Generalised oedema	08.01.07.004; 14.05.06.007	0.000112%
Glossitis	07.14.01.001	0.000168%		Not Available
Granulocytopenia	01.02.03.003	0.000168%		Not Available
Groin pain	15.03.02.004	0.000112%		Not Available
Haematemesis	24.07.02.011; 07.12.02.002	0.000504%		Not Available
Haematuria	21.10.01.018; 24.07.01.047; 20.02.01.006	0.000448%
Haemoglobinuria	20.02.01.017; 01.06.04.005	0.000112%
Haemolytic uraemic syndrome	01.06.02.001; 20.01.03.011	0.000168%
Haemoptysis	02.11.04.009; 24.07.01.006; 22.02.03.004	0.000616%		Not Available
Heart disease congenital	02.11.01.014; 03.07.07.001	-	-	Not Available
Hemianopia	17.17.01.012; 06.02.07.004	0.000112%		Not Available
Hemiparesis	17.01.04.001	0.000336%
Hemiplegia	17.01.04.002	0.000112%		Not Available
Hepatic cirrhosis	09.01.04.001	0.000280%		Not Available
Hepatic encephalopathy	17.13.01.003; 09.01.03.006	0.000224%		Not Available
Hepatic failure	09.01.03.002	0.000504%

The 5th Page First Pre 5 6 7 8 9 Next Last Total 20 Pages